» Articles » PMID: 35168646

The Prevalence and Pattern of Cannabis Use Among Patients Attending a Methadone Treatment Clinic in Nairobi, Kenya

Overview
Publisher Biomed Central
Specialty Psychiatry
Date 2022 Feb 16
PMID 35168646
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cannabis use during methadone treatment may negatively impact treatment outcomes. The aim of this study was to determine the prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya.

Methods: This was a retrospective study of 874 patients on methadone therapy at a methadone maintenance treatment clinic in Nairobi, Kenya from December 2014 to November 2018. Data on sociodemographic characteristics and drug use patterns based on urine drug screens was collected from patient files. Data was analyzed using Statistical Package for the Social Sciences (SPSS) for windows version 23.0.

Results: Point prevalence of cannabis use was 85.8% (95% CI, 83.3 - 88.0) at baseline and 62.7% (95% CI, 59.5 - 65.8) during follow-up. A pattern of polysubstance use was observed where opioids, cannabis and benzodiazepines were the most commonly used drugs. The mean age of the patients was 35.3 (SD 9.0) years with the majority being male, unemployed (76%), (51.4%) had reached primary level of education, and (48.5%) were divorced or separated. University education was associated with reduced risk for cannabis use OR = 0.1 (95% CI, 0.02-0.8, p = 0.031).

Conclusion: Cannabis use is prevalent among patients attending a methadone treatment clinic in Kenya, suggesting need for targeted interventions to address the problem of cannabis use during methadone treatment.

Citing Articles

The burden of unlawful use of opioid and associated epidemiological characteristics in Africa: A scoping review.

Onohuean H, Oosthuizen F PLoS One. 2025; 20(3):e0317036.

PMID: 40053543 PMC: 11888143. DOI: 10.1371/journal.pone.0317036.


Trends of the Global Burden of Disease Attributable to Cannabis Use Disorder in 204 Countries and Territories, 1990-2019: Results from the Disease Burden Study 2019.

Shao H, Du H, Gan Q, Ye D, Chen Z, Zhu Y Int J Ment Health Addict. 2023; :1-23.

PMID: 36817983 PMC: 9913032. DOI: 10.1007/s11469-022-00999-4.


Synthetic cannabinoids use in a sample of opioid-use disorder patients.

Alias-Ferri M, Pellegrini M, Marchei E, Pacifici R, Rotolo M, Pichini S Front Psychiatry. 2022; 13:956120.

PMID: 35990071 PMC: 9381952. DOI: 10.3389/fpsyt.2022.956120.

References
1.
Suzuki J, Weiss R . Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence?. J Addict Med. 2020; 15(2):91-92. PMC: 7986228. DOI: 10.1097/ADM.0000000000000711. View

2.
Degenhardt L, Ferrari A, Calabria B, Hall W, Norman R, McGrath J . The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013; 8(10):e76635. PMC: 3811989. DOI: 10.1371/journal.pone.0076635. View

3.
Mayet A, Lions C, Roux P, Mora M, Maradan G, Morel A . Variations in Cannabis Use Level and Correlates in Opiate-Users on Methadone Maintenance Treatment: A French Prospective Study. J Subst Abuse Treat. 2015; 58:100-5. DOI: 10.1016/j.jsat.2015.06.015. View

4.
Wiese B, Wilson-Poe A . Emerging Evidence for Cannabis' Role in Opioid Use Disorder. Cannabis Cannabinoid Res. 2018; 3(1):179-189. PMC: 6135562. DOI: 10.1089/can.2018.0022. View

5.
Bawor M, Dennis B, Varenbut M, Daiter J, Marsh D, Plater C . Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. Biol Sex Differ. 2015; 6:21. PMC: 4640383. DOI: 10.1186/s13293-015-0038-6. View